HES1 and prostate carcinoma: Because γ-secretase inhibitor DAPT reduced Hes1 level in prostate cancer cell lines [19] (see also Figure 7), we sought to explore whether the γ-secretase inhibition-mediated increases in δ-catenin expression is accompanied by phenotypic changes with implications of neuroendocrine alterations.